BEOGRAD, Serbia, Oct. 12 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com (HTDS) - The issuer's Serbia based operating subsidiary Slavica Bio Chem www.slavicabiochem.com is providing an audio recording and a transcript of its message via Pink Sheets Filing service. The audio recording a wav file can be played by visiting www.minamargroup.com/htds.
The transcript and the audio recording covers scientific topics and work being done by the issuer's Serbian Slavica Bio Chem operating subsidiary. Other topics touched or addressed are Multiple Sclerosis and Traumatic Brain Injury, The newly founded MindUp project is dealing with cancer treatment. Team leader from Slavica Biochem is Dr Mirjana Stojiljkovic of the Institute of Biological Research "Sinisa Stankovic," Belgrade, Serbia. The MindUp cancer project is to be affiliated and or sold or assigned (transaction not yet ratified) to a Canadian Pharmaceutical company. This is the introduction of Dr. Sabera Ruzdijic as chief scientist of MindUp the cancer project.
Substances used include existing in-use drugs, such as RIBAVIRIN and TIAZOFURIN. RIBAVIRIN an already FDA approved drug and used in human clinical practice as antiviral drug, by the trade name: VIRAZOLE(R) There has been very successful treatment of Respiratory Syncytial Virus in children, hepatitis C, SARS and HIV. TIAZOFURIN. It has been granted orphan-drug status by FDA for the Treatment of Chronic Myelogenous Leukemia (CML). There are Phase II clinical trials of anticancer drugs.
This is experimental data that Slavica Biochem group obtained on laboratory animals. Preliminary experiments will begin within a project aimed at promoting stem cell graft survival in the model of traumatic brain injury in rats.
The company invites its followers to review all the Pink Sheets filings and the full transcript and to listen to the audio recording of the scientists in Belgrade.
In other company news, HTDS management has been informed that there is an independent petition brought by a number of shareholders in support of HTDS at http://www.petitiononline.com/htds2009/petition.html. This is a petition to the Pink Sheets to remove the Caveat Emptor status from HTDS stock listing. To date, over 600 concerned shareholders have clicked on that link and signed the petition!
To our shareholders: We share your concern that the action of the Pink Sheets in giving us the skull and crossbones and failing to remove for so long is hurting our stock price and causing people not to buy our stock. We agree that the reason given for continuing this improper action -- that there may be other people making naked short sales in the stock -- is not a good reason to negatively label our company. We know of no other instance where this has happened to another company in the Pink Sheets whose stock has short sellers. We are making every effort to remedy this situation.
On behalf of HTDS management, employees and the patients that we help with our treatments, we thank our shareholders for their strong support. We are all grateful for such loyal shareholders and their spontaneous demonstration of confidence in the future of our company. We pledge to re-double our efforts to create value for you no matter what opposition we face.
To receive regular updates on HTDS please sign up or opt in with your email address at this link http://www.minamargroup.com/updates/
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project", and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact firstname.lastname@example.org; For any corporate matters, please contact www.minamargroup.com/helpdesk; Investor Relations Department, (302) 357-9915 (IR); 1st Level Support Retail Clients General Inquiry, 1-800-365-4331 (M&A); Corporate Matters, www.minamargroup.com (M&A), www.minamargroup.net (IR)
SOURCE Hard to Treat Diseases
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved